MedTrace Logo

Combination of Metformin With Gefitinib to Treat NSCLC

NCT01864681 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2018-06-20

No results posted yet for this study

Summary

The purpose of this study is to determine whether metformin in combination with gefitinib are effective in patients with previously untreated advanced or metastatic Non-Small-Cell Lung cancer with epidermal growth factor receptor (EGFR) mutations

Conditions

Interventions

DRUG

Gefitinib and Metformin

Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.

DRUG

Gefitinib and placebo

Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.

Sponsors & Collaborators

  • Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

    lead OTHER

Principal Investigators

  • Yong He, MD · Daping Hospital, Third Military Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2017-12-31
Completion
2018-06-04

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01864681 on ClinicalTrials.gov